Medicaid AMPs Would Be Replaced By Pharmacy Acquistion Cost - House Bill
Executive Summary
Federal payment limits on Medicaid outpatient prescription drugs would be based on community pharmacy retail acquisition costs, under legislation introduced July 24 by Reps. Nancy Boyda, D-Kan., and Jo Ann Emerson, R-Mo
You may also be interested in...
Medicaid AMPs Should Be Limited To A-Rated Drugs – Pharmacy Lawsuit
Medicaid's drug payment limits will be applied illegally to non-equivalent drugs under the program's average manufacturer price rules, the National Association of Chain Drug Stores and National Community Pharmacists Association argue in a lawsuit filed Nov. 7
Medicaid AMPs Should Be Limited To A-Rated Drugs – Pharmacy Lawsuit
Medicaid's drug payment limits will be applied illegally to non-equivalent drugs under the program's average manufacturer price rules, the National Association of Chain Drug Stores and National Community Pharmacists Association argue in a lawsuit filed Nov. 7
Medicaid drug bill introduced in Senate
The Fair Medicaid Payment Act of 2007, introduced Aug. 2 by Sen. Max Baucus, D-Mont., would remove mail-order transactions from the calculation of average manufacturer prices and exclude discounts, rebates and other price concessions that are not passed on to retail pharmacies. The bill, S. 1951, is being hailed by retail pharmacies as an improvement over the Medicaid drug reimbursement system created under the 2005 Deficit Reduction Act, because it uses a pricing benchmark based on acquisition costs and sets federal upper limits only when there are three or more, rather than two or more, equivalent drug products on the market. CMS recently issued its final rule establishing the AMP methodology (1"The Pink Sheet" July 23, 2007, p. 25). Similar legislation seeking to change the payment methodology was introduced in the House July 24 (2"The Pink Sheet" July 30, 2007, p. 22)...